TY - JOUR
T1 - Novel imaging modalities in gynecologic cancer
AU - Brooks, Rebecca A.
AU - Powell, Matthew A.
PY - 2009
Y1 - 2009
N2 - Novel imaging modalities continue to emerge in medicine, and the advent of 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has had a significant impact in the imaging of gynecologic malignancies. In cervical cancer, FDG-PET has excellent sensitivity and specificity for evaluation of initial disease, as well as assessment of post-treatment response and long-term surveillance. In ovarian cancer, FDG-PET can be a useful tool in assessing recurrent disease, especially in the setting of a rising cancer antigen-125 with a negative or equivocal CT or MRI. In uterine cancer, FDG-PET has been investigated in evaluating the extent of disease including nodal metastases, and in assessing recurrence. This article reviews novel imaging modalities in gynecologic cancer, with a special focus on FDG-PET/CT.
AB - Novel imaging modalities continue to emerge in medicine, and the advent of 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has had a significant impact in the imaging of gynecologic malignancies. In cervical cancer, FDG-PET has excellent sensitivity and specificity for evaluation of initial disease, as well as assessment of post-treatment response and long-term surveillance. In ovarian cancer, FDG-PET can be a useful tool in assessing recurrent disease, especially in the setting of a rising cancer antigen-125 with a negative or equivocal CT or MRI. In uterine cancer, FDG-PET has been investigated in evaluating the extent of disease including nodal metastases, and in assessing recurrence. This article reviews novel imaging modalities in gynecologic cancer, with a special focus on FDG-PET/CT.
UR - http://www.scopus.com/inward/record.url?scp=70350153115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350153115&partnerID=8YFLogxK
U2 - 10.1007/s11912-009-0063-x
DO - 10.1007/s11912-009-0063-x
M3 - Review article
C2 - 19840524
AN - SCOPUS:70350153115
VL - 11
SP - 466
EP - 472
JO - Current Oncology Reports
JF - Current Oncology Reports
SN - 1523-3790
IS - 6
ER -